Bio-Techne
TECH
72.67
-0.03
-0.04%
Bio-Techne
US · TECH
#1365 by market cap
Listed 1970
72.67
-0.03
-0.04%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 5.6 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 108.46% -5.65pp
- Institutions
- 697 +3
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund77.16%
Hedge Fund16.05%
Public Company10.34%
Private Company1.71%
Government Pension Fund1.47%
Sovereign Wealth Fund0.90%
Family Office/Trust0.46%
Individual/Insider0.36%
Insurance Company0.16%
Top holders as of 2026-09-30
BlackRock
9.07% · 14.25M sh
FMR
8.14% · 12.76M sh
Vanguard Capital Management, LLC
6.53% · 10.25M sh
HBK Investments L.P.
4.34% · 6.83M sh
Vanguard Portfolio Management, LLC
4.04% · 6.35M sh
The Goldman Sachs Group, Inc.
3.99% · 6.27M sh
Fidelity International Ltd
3.99% · 6.27M sh
State Street Global Advisors
3.85% · 6.05M sh
Geode Capital Management, LLC
3.46% · 5.43M sh
Eaton Vance Management
3.04% · 4.78M sh
Invesco Capital Management LLC
2.89% · 4.54M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| James Hippel | Chief Financial Officer | 0.11% |
| Kim Kelderman | Chief Executive Officer | 0.05% |
| John Higgins | Independent Director | 0.05% |
| Robert Baumgartner | Independent Chairperson | 0.04% |
| Roeland Nusse | Former Independent Director | 0.03% |
| William Geist | President of Protein Sciences Segment | 0.02% |
| Joseph Keegan | Independent Director | 0.01% |
| Alpna Seth | Independent Director | 0.01% |
| S.J. Vessey | Independent Director | 0.01% |
| Shane Bohnen | Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer | 0.01% |
| Julie Bushman | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-31 | Kim Kelderman | Chief Executive Officer | Sale to Issuer | -2,385 | $72.66 |
| 2026-10-31 | James Hippel | Chief Financial Officer | Derivative Exercise and Sale | -5,096 | $72.66 |
| 2026-10-31 | James Hippel | Chief Financial Officer | Derivative Exercise and Retained | +6,449 | -- |
| 2026-10-28 | Robert Baumgartner | Independent Chairperson | Other Acquisition | +2,750 | -- |
| 2026-10-28 | John Higgins | Independent Director | Other Acquisition | +2,750 | -- |
| 2026-10-28 | Joseph Keegan | Independent Director | Other Acquisition | +2,750 | -- |
| 2026-10-28 | Julie Bushman | Independent Director | Other Acquisition | +2,750 | -- |
| 2026-10-28 | Alpna Seth | Independent Director | Other Acquisition | +2,750 | -- |
| 2026-10-28 | Amy Herr | Independent Director | Other Acquisition | +2,750 | -- |
| 2026-10-28 | Judith Klimovsky | Independent Director | Other Acquisition | +2,750 | -- |
| 2026-10-28 | S.J. Vessey | Independent Director | Other Acquisition | +2,750 | -- |
| 2026-09-27 | John Higgins | Independent Director | Derivative Exercise and Sale | -5,562 | $72.51 |
| 2026-09-27 | John Higgins | Independent Director | Derivative Exercise and Retained | +10,378 | -- |
| 2026-09-21 | Robert Baumgartner | Independent Chairperson | Derivative Exercise and Sale | -5,559 | $72.55 |
| 2026-09-21 | Robert Baumgartner | Independent Chairperson | Derivative Exercise and Retained | +10,381 | -- |
| 2026-08-16 | Kim Kelderman | Chief Executive Officer | Other Derivative Acquisition | +151,172 | -- |
| 2026-08-16 | Steven Crouse | President of Diagnostics & Spatial Biology Segment | Other Derivative Acquisition | +22,842 | -- |
| 2026-08-16 | James Hippel | Chief Financial Officer | Other Derivative Acquisition | +58,897 | -- |
| 2026-08-16 | Amy Herr | Independent Director | Other Derivative Acquisition | +1,381 | -- |
| 2026-08-16 | William Geist | President of Protein Sciences Segment | Other Derivative Acquisition | +38,747 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.
Bio-Techne discussion 0 comments